Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression

Kumiko Yamamoto1, Sachio Ito1, Hiroko Hanafusa1

  • 1Department of Molecular Genetics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, Japan.

Plos One
|September 15, 2015
PubMed

Insights

MicroRNAs (miRNAs) regulate gene expression. This study identifies four direct targets of miR-19a, a key microRNA in lung cancer, revealing their role in tumor suppression and potential as therapeutic targets.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression, influencing approximately 30% of human genes.
  • Emerging evidence links specific miRNAs to lung cancer development, with miR-19a identified as a crucial oncogenic miRNA.
  • The direct targets of miR-19a in lung tumorigenesis remain largely uncharacterized, hindering therapeutic development.

Purpose of the Study:

  • To identify and validate direct target genes of miR-19a.
  • To investigate the functional role of validated miR-19a targets in lung cancer cells.
  • To explore the potential of miR-19a targets as therapeutic targets for lung cancer.

Main Methods:

  • Bioinformatic prediction of potential miR-19a target genes.
  • Luciferase reporter assays, pull-down assays, and Western blot analysis to validate direct miR-19a targets.
  • Functional assays (cell viability, colony formation, migration, invasion) using lung cancer cell lines with varying miR-19a expression levels.

Main Results:

  • Four genes—FOXP1, TP53INP1, TNFAIP3, and TUSC2—were validated as direct targets of miR-19a.
  • Expression levels of these four target proteins were inversely correlated with miR-19a expression in lung cancer cells.
  • Overexpression of these target genes suppressed cell viability, colony formation, migration, and invasion in lung cancer cells.

Conclusions:

  • FOXP1, TP53INP1, TNFAIP3, and TUSC2 are direct targets of miR-19a, playing a tumor-suppressive role in lung cancer.
  • These validated miR-19a targets represent potential biomarkers and therapeutic targets for lung cancer intervention.
  • Further research into the specific mechanisms of these targets could lead to novel lung cancer treatments.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K